Award & Investment Overview
Senticell has closed an oversubscribed seed financing round approaching $7 million to advance a liquid biopsy platform exclusively licensed from the University of Pennsylvania and based on research pioneered at Penn Medicine.
The financing included participation from The Venture City, Capital Factory, Scalpel Ventures, Evoce Capital, and a group of high-net-worth individuals. Senticell plans to use the capital to advance multiple oncology clinical studies evaluating its red blood cell-based liquid biopsy technology.
The financing represents an important commercialization milestone for a university-licensed diagnostic technology. Senticell is moving beyond foundational research and technology licensing into prospective clinical validation, using venture capital to generate evidence around detection performance, tissue concordance, and disease monitoring.
Approach & Ecosystem Context
Senticell’s platform is based on more than a decade of published research at Penn Medicine demonstrating that red blood cells can bind and retain disease-associated DNA and RNA. The underlying insights were first identified by Nilam Mangalmurti, MD, scientific co-founder and chief scientific advisor of Senticell. The company holds an exclusive worldwide license from the University of Pennsylvania to the foundational RBC platform.
The commercialization pathway remains closely connected to Penn following licensing. Two prospective clinical studies are underway at Penn Medicine and together are expected to enroll approximately 300 patients.
One study is enrolling approximately 200 patients with lung and pancreatic cancers at Penn to evaluate pre-surgical driver detection and recurrence monitoring. Completion is expected in Q1 2027.
A second study involving approximately 100 patients across Penn and Penn-Botswana is evaluating RBC-based analysis in head and neck and cervical cancer cohorts for minimal residual disease and post-treatment monitoring. Results are expected in Q4 2026.
Senticell also maintains a Sponsored Research Agreement with Penn Medicine supporting foundational work on rapid, culture-independent pathogen detection for sepsis and pneumonia. The company expects to establish a dedicated clinical study around infectious disease applications after completing its initial oncology proof-of-concept work.
From a Mind the GAP perspective, Senticell demonstrates how university commercialization support can extend beyond intellectual property licensing. The pathway connects Penn-originated research and licensed IP with sponsored research, access to clinical study infrastructure, company formation, and external seed investment.
The nearly $7 million financing is particularly important because it funds the evidence-generation stage required to move a university technology toward a commercially viable diagnostic platform. Successful clinical validation can reduce technical and clinical risk while creating stronger proof points for future regulatory development, strategic partnerships, and follow-on investment.
Innovation & Technology
Senticell is developing a liquid biopsy platform based on red blood cell-bound nucleic acids.
Conventional liquid biopsy approaches commonly analyze circulating material found in plasma. Senticell’s platform instead seeks to capture and analyze disease-associated DNA and RNA bound to red blood cells.
Red blood cells are highly abundant, remain in circulation for roughly 120 days, and interact with tissues throughout the body. Research underlying Senticell suggests they may provide access to molecular signals that are difficult to detect consistently using plasma-based testing alone.
The company has developed technology to isolate and rapidly analyze RBC-associated nucleic acids, including oncogenic driver mutations. Its initial development strategy focuses on oncology, including early-stage disease and low-shedding tumors where conventional liquid biopsy can face sensitivity limitations.
Senticell’s current prospective studies are designed to compare RBC-derived signals with plasma-based testing and evaluate concordance with tissue findings. These studies represent important validation milestones because they move the platform from academic and analytical evidence toward performance data generated in clinically relevant patient populations.
Potential Market Uses and Applications
Potential Oncology Applications
- Early cancer detection
- Lung cancer testing
- Pancreatic cancer testing
- Pre-surgical oncogenic driver detection
- Cancer recurrence monitoring
- Minimal residual disease detection
- Post-treatment monitoring
- Liquid biopsy for early-stage and low-shedding tumors
Potential Infectious Disease Applications
- Sepsis detection
- Pneumonia diagnostics
- Rapid pathogen detection
- Culture-independent infectious disease testing
Potential Diagnostic Platform Applications
- Red blood cell-based molecular diagnostics
- Nucleic acid analysis
- Longitudinal disease monitoring
- Clinical laboratory testing
- Oncology diagnostic development
Related Topics
University of Pennsylvania, Penn Medicine, Senticell, university technology licensing, liquid biopsy, red blood cell diagnostics, cancer diagnostics, oncology, molecular diagnostics, seed financing, venture investment, clinical validation, sponsored research, translational research, diagnostic commercialization
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more:
